Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Xspray Pharma AB (publ) is a Sweden-based pharmaceutical company specializing in the development of innovative amorphous product candidates using its patented HyNap technology platform. The company focuses on creating improved versions of marketed protein kinase inhibitors (PKIs), primarily for cancer treatments such as chronic myeloid leukemia, liver cancer, renal cell cancer, and differentiated thyroid cancer. Key product candidates include Dasynoc, an enhanced formulation of dasatinib nearing FDA approval and commercialization in the US market in 2025, as well as HyNap-Nilo (nilotinib), HyNap-Sora (sorafenib), XS003 (axitinib), and XS025 (cabozantinib). These products offer advantages like higher bioavailability, reduced dosing, and better patient outcomes compared to crystalline originals and generics, enabling market entry upon expiration of primary drug substance patents. Xspray Pharma's strategy emphasizes a shorter development timeline via the 505(b)(2) pathway, robust patent protection, and partnerships for production and commercialization. With around 26-30 employees and headquarters in Solna, the firm targets the multi-billion-dollar oncology market, positioning itself as a leader in life-cycle management for PKIs amid growing demand for superior therapies.
kr 1.29
+kr 0.05 (+3.69%)
Live · 10:03 PM · Twelve Data
Negative free cash flow of -kr 222M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
kr 0.00
Net Income (FY)
-kr 171M
▲ +40.0% YoY
Op. Margin
—
ROIC
-16.71%
▲ +13.5pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-kr 222M
▲ +15.9% YoY
Op. Cash Flow (FY)
-kr 187M
▲ +25.9% YoY
Net Debt
-kr 5M
Net Cash Position
Cash & Equiv.
kr 154M
Continue Research
Xspray Pharma AB (publ) (XSPRAY.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Xspray Pharma AB (publ) scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Xspray Pharma AB (publ) scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -16.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh XSPRAY.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.